Patient-reported outcome (PRO) data were collected as part of Study 3004. The Applicant chose to use the Breast Cancer Specific Quality of Life – Functional Assessment of Cancer Therapy (FACT)-B (version 4), a 37-item questionnaire and the EuroQol five dimension questionnaire (EQ-5D), an instrument used to assess generic health status and outcomes. The PRO analysis was considered exploratory with the stated study objective of better understanding the perspective of the patient experience during neratinib therapy in the extended adjuvant setting. PRO data were collected up to Amendment 9.